If your employer is interested in identifying new biomarkers for oncology and immunology therapies, you should be investigating HLA-typing of new and legacy data. There is considerable insight to be gained from these exciting new research opportunities.
Human Leukocyte Antigen (HLA) typing has long been a standard tool for tissue matching in transplant medicine, however the HLA region also has significant applications for oncology biomarkers, disease association and pharmacogenomics. And with the recent advent of next-generation sequencing technology and advances in statistical phasing, there are now multiple, cost-effective options to HLA-type individuals in addition to the current “gold standard” technology of “Sequence-Based Typing”, or SBT.
Some of these innovations are also...